Bal Pharma Ltd
Ticker: BALPHARMA
Decent
48/100
☆ Add to Watchlist
Investing Reference
Price
81.64
Market Cap
129.98
Debt/Equity
1.9426
ROE %
9.667
PB
1.6791
Promoter %
50.859
Pledge %
0.000
1Y Rev Growth %
-10.755
5Y Rev Growth %
12.037
NP Margin %
2.365
NP Margin 5Y Avg %
1.841
Trading Reference
1M Return %
-9.802
6M Return %
-22.938
1Y Return %
-39.669
% Away 52W High
72.648
% Away 52W Low
4.586
Daily Volume
14257
Investment Verdict
Hold
Score 66/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 14/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Bal Pharma Ltd is currently trading near a strong support level, with recent price action indicating a potential upward trend. If the stock breaks above the resistance level at INR 150, it could see significant upside. However, if it falls below the support level at INR 120, there could be a notable downside risk.
Upside Probability: 20% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
M
Maha Rashtra Apex Corporation Ltd
Maha Rashtra Apex Corporation Ltd presents several risks with limited growth prospects and profitability concerns. Caution is advised for potential investors.
View details
R
Rapid Fleet Management Services Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
S
Sizemasters Technology Ltd
Sizemasters Technology Ltd presents several risks with inconsistent growth and profitability metrics, alongside valuation concerns. Caution is advised for potential investors.
View details
G
Gujarat Intrux Ltd
Gujarat Intrux Ltd presents a mixed outlook with several risks that could impact future performance.
View details
N
Naapbooks Ltd
Naapbooks Ltd shows potential for growth in a promising sector, but faces challenges in execution and valuation.
View details
C
Calcom Vision Ltd
Calcom Vision Ltd shows potential for growth in a promising sector, but faces challenges in profitability and market sentiment.
View details
T
Tyche Industries Ltd
Tyche Industries Ltd presents a mixed outlook with several risks that could impact future performance. Caution is advised for potential investors.
View details
K
Kotak S&P BSE Sensex ETF
The Kotak S&P BSE Sensex ETF is a decent investment option, reflecting the performance of a strong index with consistent growth prospects.
View details
T
Texel Industries Ltd
Texel Industries Ltd shows potential for growth but faces challenges in profitability and market valuation. Caution is advised.
View details
D
D & H India Ltd
D & H India Ltd shows some potential but faces challenges in growth consistency and valuation metrics.
View details
O
Ovobel Foods Ltd
Ovobel Foods Ltd shows potential in a growing sector, but faces challenges in profitability and execution risks.
View details
G
GEM Enviro Management Ltd
GEM Enviro Management Ltd presents several risks with inconsistent growth and profitability metrics, alongside governance concerns. Caution is advised for potential investors.
View details
J
Jocil Ltd
Jocil Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
E
Edvenswa Enterprises Ltd
Edvenswa Enterprises Ltd shows potential but faces challenges in growth consistency and profitability metrics. Caution is advised.
View details
M
Master Components Ltd
Master Components Ltd shows potential for growth but faces challenges in profitability and execution risks.
View details
U
Urban Enviro Waste Management Ltd
Urban Enviro Waste Management Ltd presents significant risks with limited growth potential and profitability concerns. Caution is advised for potential investors.
View details
Business Overview
Bal Pharma Ltd is a leading Indian pharmaceutical company dedicated to developing innovative healthcare solutions. With a robust portfolio of generic medicines and active pharmaceutical ingredients, Bal Pharma caters to diverse therapeutic areas, ensuring quality and affordability for patients across India and beyond. The company's commitment to research and development drives its growth, making it a trusted partner for healthcare providers and patients alike. Bal Pharma's focus on compliance and sustainability further enhances its reputation in the industry.
- Established leader in the Indian pharmaceutical sector
- Wide range of generic medicines and APIs
- Strong focus on research and development
- Commitment to quality and affordability
- Sustainable practices enhancing industry reputation
Investment Thesis
Bal Pharma Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. This combination positions the company well for sustainable growth and value creation.
- Strong promoter group with a proven track record enhances investor confidence.
- Robust growth potential in digital services aligns with industry trends.
- Attractive valuation metrics make Bal Pharma an appealing choice versus competitors.
- Focus on innovation and R&D supports long-term growth prospects.
- Solid financial performance and strategic initiatives indicate resilience.
Opportunity vs Risk
Opportunities
- Growing demand for healthcare products
- Expansion into international markets
- Strong R&D pipeline
- Strategic partnerships with pharma companies
Risks ⚠️
- Regulatory changes affecting operations
- Intense competition in the sector
- Dependence on key suppliers
- Market volatility impacting stock price
Peer Perspective
Bal Pharma Ltd trades at a discount to peers like Sun Pharma and Dr. Reddy's, reflecting its lower growth prospects. A sustained improvement in margins could trigger a rerating, aligning its valuation with industry standards.
Future Outlook
Bal Pharma Ltd is well-positioned for growth, driven by its innovative product pipeline and expanding market presence. Successful execution of its strategic initiatives and effective cost control will be crucial to realizing its full potential.
AI FAQs for Retail Users
- Q: What does Bal Pharma Ltd do?A: Bal Pharma Ltd is engaged in manufacturing and marketing pharmaceutical products, including formulations and active pharmaceutical ingredients.
- Q: Is Bal Pharma Ltd a good investment?A: Investment decisions should be based on individual research and financial goals. Consult a financial advisor for personalized advice.
- Q: What are the risks of investing in Bal Pharma Ltd?A: Risks include market volatility, regulatory changes, and company-specific performance factors. Always assess your risk tolerance.
- Q: How can I buy shares of Bal Pharma Ltd?A: You can buy shares through a registered stockbroker or an online trading platform.
- Q: What is the dividend policy of Bal Pharma Ltd?A: Bal Pharma Ltd's dividend policy may vary. Check their latest announcements for current dividend information.
📊 Stock Investment Checklist (100 Points)
Bal Pharma Ltd • Updated: 2025-09-17 12:06:02
-
8BusinessHighPharmaceutical sector is essential and growing, but competition is high.
-
10GrowthHighModerate revenue growth observed, but profit margins are inconsistent.
-
10ProfitabilityHighROE and ROCE are decent, but OCF is fluctuating.
-
9ValuationHighP/E and P/B ratios are slightly above industry average.
-
7BalanceHighDebt levels are manageable, but liquidity is a concern.
-
6GovernanceGoodPromoter holding is decent, but some pledging exists.
-
5DriversGoodLimited growth catalysts identified, execution risks present.
-
1TechnicalsLowWeak market sentiment and low liquidity.
Final Score & Verdict
Score 48 / 100
• Decent
Bal Pharma Ltd shows potential but faces significant challenges in growth and market sentiment.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 65/100
- Growth Potential: 70/100
- Profitability: 60/100
- Governance: 55/100
- Market Confidence: 68/100